Data / Drug companies / Diagnostic Dye
Diagnostic Dye drugs: 5 drugs from 16 companies in the FDA NDC directory
Diagnostic Dye is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 22 products in this class from 16 companies, covering 5 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on October 14, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 16Companies
- 22Products
- 5Drugs by generic name
Drugs in the Diagnostic Dye class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Fluorescein | 11 | 8 |
| Fluorescein sodium and benoxinate hydrochloride | 3 | 3 |
| Fluorescein sodium | 4 | 2 |
| Indigotindisulfonate sodium | 2 | 2 |
| Trypan blue | 2 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Nomax Inc. | 3 | strip | Other unapproved drugs | December 5, 2013 |
| D.o.r.c. Dutch Ophthalmic Research Center (International) B.V. | 2 | injection, solution | New drug applications (NDA) | February 20, 2009 |
| Nexus Pharmaceuticals LLC | 2 | injection | Generic drugs (ANDA) | October 24, 2023 |
| Zydus Lifesciences Limited | 2 | injection | Generic drugs (ANDA) | June 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | 2 | injection | Generic drugs (ANDA) | June 2, 2026 |
| Alcon Laboratories, Inc. | 1 | injection, solution | New drug applications (NDA) | September 15, 1972 |
| Altaire Pharmaceuticals Inc. | 1 | solution | New drug applications (NDA) | March 1, 2018 |
| Anthea Pharma Private Limited | 1 | injection | Generic drugs (ANDA) | October 14, 2026 |
| Bausch & Lomb Americas Inc. | 1 | solution/ drops | Authorized generics (NDA) | March 20, 2020 |
| Bausch & Lomb Incorporated | 1 | solution/ drops | New drug applications (NDA) | March 20, 2020 |
| Bpi Labs LLC | 1 | injection, solution | Generic drugs (ANDA) | May 20, 2026 |
| HF Acquisition Co LLC, DBA HealthFirst | 1 | injection | New drug applications (NDA) | May 10, 2021 |
| Long Grove Pharmaceuticals, LLC | 1 | injection | New drug applications (NDA) | September 28, 2024 |
| Provepharm Inc. | 1 | injection | New drug applications (NDA) | September 6, 2022 |
| Sagent Pharmaceuticals | 1 | injection | New drug applications (NDA) | April 15, 2026 |
| Vistamerica USA | 1 | strip | Other unapproved drugs | October 1, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 11 | 50% |
| Strip | 4 | 18.2% |
| Injection, solution | 4 | 18.2% |
| Solution/ drops | 2 | 9.1% |
| Solution | 1 | 4.5% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.